Status:

WITHDRAWN

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19

Lead Sponsor:

University of California, Irvine

Collaborating Sponsors:

Hudson Valley Healing Arts Center

Conditions:

COVID-19

Eligibility:

All Genders

18+ years

Phase:

EARLY_PHASE1

Brief Summary

The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be r...

Eligibility Criteria

Inclusion

  • • Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list

Exclusion

  • • History of a severe sulfa sensitivity (i.e., anaphylaxis, Stevens Johnson Syndrome), allergy to meat products and/or gelatin (alpha gal allergy) and/or a history of an allergic or adverse reaction to NAC, alpha lipoic acid and/or GSH.

Key Trial Info

Start Date :

June 1 2025

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

November 1 2025

Estimated Enrollment :

Patients enrolled

Trial Details

Trial ID

NCT05371288

Start Date

June 1 2025

End Date

November 1 2025

Last Update

November 5 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University of California Irvine Medical Center

Orange, California, United States, 92868

The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19 | DecenTrialz